K36 Therapeutics
Founded 2021 · 14 employees on LinkedIn · 6 known investors
Find your way into K36 Therapeutics
A biotechnology company developing cancer therapies for patients with unmet medical needs. Its clinical pipeline includes the KTX-1001 and KTX-2001 programs.
Investors · 6
Atlas VentureCambridge · $500K – $1M
F-Prime CapitalCambridge · $3M – $10M
Nextech InvestZurich · $648K – $3.2M
Eight Roads VenturesreportedMumbai · $5M – $30M
Also in the syndicate · 2
Bristol Myers SquibbBristol Myers Squibb Company
Funding
SEC filings, press & company announcements$70M disclosed across 1 round · 2023
- $70Mseries BJun 2023 · 4 sources
Nextech Invest (lead), Atlas Venture, Bristol Myers Squibb, Bristol Myers Squibb Company, Eight Roads Ventures, F-Prime Capital
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does K36 Therapeutics do?
- A biotechnology company developing cancer therapies for patients with unmet medical needs. Its clinical pipeline includes the KTX-1001 and KTX-2001 programs.
- Who are K36 Therapeutics's investors?
- K36 Therapeutics's investors include Atlas Venture, F-Prime Capital, Nextech Invest, Eight Roads Ventures.
- How much funding has K36 Therapeutics raised?
- K36 Therapeutics has disclosed $70M raised across 1 round.